Introduction
• Gout is a chronic debilitating inflammatory arthritis caused by chronic high serum uric acid (sUA) levels (hyperuricemia), leading to deposition of monosodium urate crystals in joints, kidneys, and other connective tissue 1, 2 • Gout is estimated to affect 3.9% of US adults, 3 and prevalence is increasing worldwide 4, 5 • Uncontrolled gout can result in chronic inflammation, acute gout flares, painful, disfiguring tophi, kidney stones, and uric acid nephropathy 1, 2 • EULAR and ACR guidelines recommend target sUA levels of <6 mg/dL (357 μmol/L) (<5 mg/dL [297 μmol/L] for tophaceous gout and/or frequent flares) and monitoring every 6 months 6 -Many patients are not monitored as recommended or adequately controlled, have elevated sUA levels, and multiple flares and tophi 6 • Gout can result in decreased health-related quality of life [7] [8] [9] and work productivity, greater activity impairment, 10, 11 and higher resource use 10, 12 -Total annual US cost attributed to gout may be >$6 billion 6 
Objective
• Primary objective: Investigate the relationship between controlled gout and estimated health care resource use costs
• Secondary objective: Examine whether common comorbidities exacerbate the relationship between resource use in subjects with controlled or uncontrolled gout
Methods

Source
• Data were from the 2012 (N=71,157) and 2013 (N=75,000) US National Health and Wellness Survey (NHWS), a national, Internet-based health survey (Study D5310R00008)
• Respondents were recruited from an Internet panel using a random stratified sampling framework to ensure demographic composition was similar to that of the adult population based on governmental statistics
• All NHWS information is based on self-reporting, including diagnoses and laboratory measurements
Sample
• A total of 3729 respondents reported a gout diagnosis -Of those, 2215 were classified as having uncontrolled gout and 344 as controlled gout, based on uric acid levels and number of flares
• Those whose control status was unknown due to missing sUA levels or flares were omitted from analyses (n=1170)
• Those with controlled and uncontrolled gout were compared with no-gout controls (n=126,360)
• Additionally, those with controlled/uncontrolled gout were further examined by presence of common comorbidities 
Statistical Analysis
• Initial comparisons used 1-way analyses of variance (ANOVAs), and chi-squares were conducted to determine if the controlled gout and uncontrolled gout populations differed on demographics and health characteristics
• Additionally, 1-way ANOVAs with pairwise comparisons and chi-squares were conducted to examine the relationship of controlled gout on costs with and without comorbidities
• To initially examine the unique burden of uncontrolled gout with or without comorbidities for total costs, negative binomial generalized linear models controlling for covariates were conducted
• To better assess the fit of the data, a zero-inflated negative binomial regression controlling for covariates was run to examine the burden of uncontrolled gout for total costs
Results
Patient Demographics and Health Characteristics
• Controlled gout patients (relative to uncontrolled gout patients) ( 
Limitations
• Data was self-reported. Diagnoses of gout and comorbidities were not validated through patient charts; past research shows comparability between prevalence estimates/self-reported diagnoses in NHWS [8] [9] [10] • Flare episodes and sUA measurements are likely subject to recall bias; however, participants were not required to fill out flare episodes and sUA measurements if they could not remember, thus limiting bias in responses
• Data are cross-sectional and do not allow for causal inferences
• Sample size was also limited, particularly for controlled gout. While there were large differences in cost between uncontrolled and controlled gout, we were unable to detect significance due to small sample sizes and insufficient power; as a result, a more appropriate model was fit with reduced covariates to account for this limitation
Total Costs by Gout Control and Comorbidities ( Table 2) • The negative binomial generalized linear models showed uncontrolled gout had significantly higher total costs than no-gout controls (P<0.001). Pattern was the same for uncontrolled gout and diabetes and uncontrolled gout and CVD (both P<0.001).
• There were no significant differences between controlled gout and uncontrolled gout or controlled gout and no-gout controls with or without comorbidities (all P>0.05)
Estimated Costs (Unadjusted Comparisons)
Direct, Indirect, and Total Costs by Gout Control (Figure 1) • Those who had uncontrolled gout had:
-Significantly higher indirect and total costs than both those with controlled gout and no-gout controls -Significantly higher direct costs than no-gout controls
• Those with controlled gout had higher direct and total costs than no-gout controls Total Costs by Gout Control ( Table 3) • The zero-inflated negative binomial regression showed that uncontrolled gout had higher total costs than controlled gout and no-gout controls; there was no significant difference between controlled gout and no-gout controls. Examination of model fit using the Vuong test indicated the zero-inflated negative binomial was a better fit than a negative binomial generalized linear model (P<0.0001) 
• Those who had uncontrolled gout and diabetes had:
-Significantly higher direct and total costs than both those with controlled gout and diabetes and no-gout/no-diabetes controls -Significantly higher indirect costs than no-gout/no-diabetes controls
• Those with controlled gout and diabetes had higher direct, indirect, and total costs than no-gout/no-diabetes controls Direct, Indirect, and Total Costs by CVD and Gout Control ( Figure 3) • Those who had uncontrolled gout and CVD had significantly higher direct, indirect, and total costs than both those with controlled gout and CVD and no-gout/no-CVD controls
• Those with controlled gout and CVD had higher direct and total costs than no-gout/no-CVD controls Estimated Costs (Adjusted Comparisons)
• Multivariate cost models were conducted using regression models based on the distribution of the cost data. Negative binomial generalized linear models were first conducted to examine the cost data controlling for confounders. A second model first assessed the probability of having any costs and then estimated the level of cost using zero-inflated negative binomial regression
